Rheumatoid Arthritis Pharmacotherapeutics Market- Global Industry Analysis And Forecast(2023-2029)


Global Rheumatoid Arthritis Pharmacotherapeutics Market size is projected to reach US$ 66.43 Bn. at the end of the forecast period at a CAGR of 2.85%.

Rheumatoid Arthritis is a chronic autoimmune disease marked by systemic inflammation, which affects not only joints but a wide range of extra-articular organs. If not treated early may lead to progressive joint deformity & increased morbidity and mortality. Some classic examples of joint deformities associated with RA are Boutonniere deformity visible in the 5th digit of the right hand, Swan neck deformity in the 5th digit of the left hand and Hallux Valgus can be seen in the foot.

Nearly 5% of women and 3% of men over the age of 65 years are affected by this. Combination therapies are being used to treat rheumatoid arthritis.Rheumatoid Arthritis Pharmacotherapeutics MarketTo know about the Research Methodology :- Request Free Sample Report

Rheumatoid Arthritis Pharmacotherapeutics Market overview:

Increasing investments in the field of R&D of drugs is contributing to the growth of the market. Along with this, the rising geriatric population also drives the market upwards. Cigarette smoking is a strong risk factor that leads to substantial growth in Rheumatoid Arthritis market. The presence of high-cost drugs and favorable reimbursement policies are the most prominent driving factors for the growth of the market. The anti –TNF factors are used as first-line treatment for RA, but owing to the launch of new biologics in the global market is likely to hamper the demand for TNF inhibitors.

Rheumatoid Arthritis Pharmacotherapeutics Market Segment Analysis:

Currently, anti-TNF is the most prominently growing segment, which is used as a first-line biologic treatment worldwide. Various anti-TNFs like Remicade, Humira, and Enbrel are prescribed for the first line of treatment.

Rheumatoid Arthritis Pharmacotherapeutics Market Regional insights:

North America dominates the global market owing to the remarkable healthcare infrastructure in the country. According to the regional analysis done, affordable health care across North America is expected to boost the market. Increasing awareness and healthcare expenditure are likely to improve the demand for rheumatoid arthritis Pharmacotherapeutics market during the forecast period. Following North America, Asia Pacific is expected to hold the second-largest share in the global market due to the growing number of unmet medical needs and increasing geriatric population.

Rheumatoid Arthritis Pharmacotherapeutics Market Scope: Inquire before buying






Global Rheumatoid Arthritis Pharmacotherapeutics Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $54.56 Bn.




Forecast Period 2023 to 2029 CAGR:
2.85%
Market Size in 2029:
US $ 66.43Bn.




 Segments Covered:
by Drug-Class
Non-steroidal anti-inflammatories (NSAIDs)
Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Methotrexate (MTX)
Hydroxychloroquine (HCQ)
Sulfasalazine (SSZ)
Corticosteroids
Analgesics
Anti- Tumor Necrosis Factor (anti-TNF




by Route of Administration
Oral
Subcutaneous
Intravenous






Rheumatoid Arthritis Pharmacotherapeutics Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Rheumatoid Arthritis Pharmacotherapeutics Market Key Players:

1. Amgen
2. Johnson & Johnson
3. Abbott
4. Abbvie Inc.
5. Pfizer Inc.
6. Celgene corporation
7. Bristol-Myers Squibb Company
8. Hoffman-La Roche Ltd.
9. UCB S.A.
10.Eli Lilly and Company
11.Gilead Sciences Inc.
12.Takeda Biosciences
13.Merck
14.Taisho Pharmaceuticals
15.Viela Bio

Frequently Asked Questions:

1. Which region has the largest share in Global Rheumatoid Arthritis Pharmacotherapeutics Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Rheumatoid Arthritis Pharmacotherapeutics Market?
Ans: The Global Rheumatoid Arthritis Pharmacotherapeutics Market is growing at a CAGR of 2.85% during forecasting period 2023-2029.

3. What is scope of the Global Rheumatoid Arthritis Pharmacotherapeutics market report?
Ans: Global Rheumatoid Arthritis Pharmacotherapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Rheumatoid Arthritis Pharmacotherapeutics market?
Ans: The important key players in the Global Rheumatoid Arthritis Pharmacotherapeutics Market are – Amgen, Johnson & Johnson, Abbott, Abbvie Inc., Pfizer Inc., Celgene corporation, Bristol-Myers Squibb Company, Hoffman-La Roche Ltd., UCB S.A., Eli Lilly and Company, Gilead Sciences Inc., Takeda Biosciences, Merck, Taisho Pharmaceuticals, and Viela Bio

5. What is the study period of this market?
Ans: The Global Rheumatoid Arthritis Pharmacotherapeutics Market is studied from 2022 to 2029. 




Global Rheumatoid Arthritis Pharmacotherapeutics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Rheumatoid Arthritis Pharmacotherapeutics Market Size, by Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Rheumatoid Arthritis Pharmacotherapeutics Market Analysis and Forecast
6.1. Rheumatoid Arthritis Pharmacotherapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Rheumatoid Arthritis Pharmacotherapeutics Market Analysis and Forecast, By Drug-Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Drug-Class
7.4. Rheumatoid Arthritis Pharmacotherapeutics Market Size (US$ Mn) Forecast, By Drug-Class
7.5. Rheumatoid Arthritis Pharmacotherapeutics Market Analysis, By Drug-Class
7.6. Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis, By Drug-Class

8. Global Rheumatoid Arthritis Pharmacotherapeutics Market Analysis and Forecast, By Route of Administration
8.1. Introduction and Definition
8.2. Key Findings
8.3. Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Route of Administration
8.4. Rheumatoid Arthritis Pharmacotherapeutics Market Size (US$ Mn) Forecast, By Route of Administration
8.5. Rheumatoid Arthritis Pharmacotherapeutics Market Analysis, By Route of Administration
8.6. Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis, By Route of Administration

9. Global Rheumatoid Arthritis Pharmacotherapeutics Market Analysis, by Region
9.1. Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, by Region
9.2. Rheumatoid Arthritis Pharmacotherapeutics Market Size (US$ Mn) Forecast, by Region
9.3. Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis, by Region

10. North America Rheumatoid Arthritis Pharmacotherapeutics Market Analysis
10.1. Key Findings
10.2. North America Rheumatoid Arthritis Pharmacotherapeutics Market Overview
10.3. North America Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Drug-Class
10.4. North America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
10.4.1. Non-steroidal anti-inflammatories (NSAIDs)
10.4.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
10.4.3. Corticosteroids
10.4.4. Analgesics
10.5. North America Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Route of Administration
10.6. North America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
10.6.1. Oral
10.6.2. Subcutaneous
10.6.3. Intravenous
10.7. North America Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, by Country
10.8. North America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.8.3. Mexico
10.9. North America Rheumatoid Arthritis Pharmacotherapeutics Market Analysis, by Country
10.10. U.S. Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
10.10.1. Non-steroidal anti-inflammatories (NSAIDs)
10.10.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
10.10.3. Corticosteroids
10.10.4. Analgesics
10.11. U.S. Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
10.11.1. Oral
10.11.2. Subcutaneous
10.11.3. Intravenous
10.12. Canada Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
10.12.1. Non-steroidal anti-inflammatories (NSAIDs)
10.12.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
10.12.3. Corticosteroids
10.12.4. Analgesics
10.13. Canada Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
10.13.1. Oral
10.13.2. Subcutaneous
10.13.3. Intravenous
10.14. Mexico Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
10.14.1. Non-steroidal anti-inflammatories (NSAIDs)
10.14.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
10.14.3. Corticosteroids
10.14.4. Analgesics
10.15. Mexico Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
10.15.1. Oral
10.15.2. Subcutaneous
10.15.3. Intravenous
10.16. North America Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis
10.16.1. By Drug-Class
10.16.2. By Route of Administration
10.17. PEST Analysis
10.18. Key Trends
10.19. Key Developments

11. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Analysis
11.1. Key Findings
11.2. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Overview
11.3. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Drug-Class
11.4. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.4.1. Non-steroidal anti-inflammatories (NSAIDs)
11.4.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.4.3. Corticosteroids
11.4.4. Analgesics
11.5. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.5.1. Oral
11.5.2. Subcutaneous
11.5.3. Intravenous
11.6. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, by Country
11.7. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, by Country
11.7.1. Germany
11.7.2. U.K.
11.7.3. France
11.7.4. Italy
11.7.5. Spain
11.7.6. Sweden
11.7.7. CIS countries
11.7.8. Rest of Europe
11.8. Germany Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.8.1. Non-steroidal anti-inflammatories (NSAIDs)
11.8.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.8.3. Corticosteroids
11.8.4. Analgesics
11.9. Germany Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.9.1. Oral
11.9.2. Subcutaneous
11.9.3. Intravenous
11.10. U.K. Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.10.1. Non-steroidal anti-inflammatories (NSAIDs)
11.10.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.10.3. Corticosteroids
11.10.4. Analgesics
11.11. U.K. Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.11.1. Oral
11.11.2. Subcutaneous
11.11.3. Intravenous
11.12. France Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.12.1. Non-steroidal anti-inflammatories (NSAIDs)
11.12.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.12.3. Corticosteroids
11.12.4. Analgesics
11.13. France Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.13.1. Oral
11.13.2. Subcutaneous
11.13.3. Intravenous
11.14. Italy Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.14.1. Non-steroidal anti-inflammatories (NSAIDs)
11.14.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.14.3. Corticosteroids
11.14.4. Analgesics
11.15. Italy Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.15.1. Oral
11.15.2. Subcutaneous
11.15.3. Intravenous
11.16. Spain Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.16.1. Non-steroidal anti-inflammatories (NSAIDs)
11.16.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.16.3. Corticosteroids
11.16.4. Analgesics
11.17. Spain Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.17.1. Oral
11.17.2. Subcutaneous
11.17.3. Intravenous
11.18. Sweden Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.18.1. Non-steroidal anti-inflammatories (NSAIDs)
11.18.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.18.3. Corticosteroids
11.18.4. Analgesics
11.19. Sweden Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.19.1. Oral
11.19.2. Subcutaneous
11.19.3. Intravenous
11.20. CIS countries Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.20.1. Non-steroidal anti-inflammatories (NSAIDs)
11.20.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.20.3. Corticosteroids
11.20.4. Analgesics
11.21. CIS countries Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.21.1. Oral
11.21.2. Subcutaneous
11.21.3. Intravenous
11.22. Rest of Europe Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
11.22.1. Non-steroidal anti-inflammatories (NSAIDs)
11.22.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.22.3. Corticosteroids
11.22.4. Analgesics
11.23. Rest of Europe Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
11.23.1. Oral
11.23.2. Subcutaneous
11.23.3. Intravenous
11.24. Europe Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis
11.24.1. By Route of Administration
11.24.2. By Drug-Class
11.25. PEST Analysis
11.26. Key Trends
11.27. Key Developments

12. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Analysis
12.1. Key Findings
12.2. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Overview
12.3. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Drug-Class
12.4. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.4.1. Non-steroidal anti-inflammatories (NSAIDs)
12.4.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.4.3. Corticosteroids
12.4.4. Analgesics
12.5. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Drug-Class
12.6. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.6.1. Oral
12.6.2. Subcutaneous
12.6.3. Intravenous
12.7. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, by Country
12.8. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. South Korea
12.8.5. Australia
12.8.6. ASEAN
12.8.7. Rest of Asia Pacific
12.9. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Analysis, by Country
12.10. China Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.10.1. Non-steroidal anti-inflammatories (NSAIDs)
12.10.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.10.3. Corticosteroids
12.10.4. Analgesics
12.11. China Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.11.1. Oral
12.11.2. Subcutaneous
12.11.3. Intravenous
12.12. India Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.12.1. Non-steroidal anti-inflammatories (NSAIDs)
12.12.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.12.3. Corticosteroids
12.12.4. Analgesics
12.13. India Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.13.1. Oral
12.13.2. Subcutaneous
12.13.3. Intravenous
12.14. Japan Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.14.1. Non-steroidal anti-inflammatories (NSAIDs)
12.14.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.14.3. Corticosteroids
12.14.4. Analgesics
12.15. Japan Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.15.1. Oral
12.15.2. Subcutaneous
12.15.3. Intravenous
12.16. South Korea Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.16.1. Non-steroidal anti-inflammatories (NSAIDs)
12.16.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.16.3. Corticosteroids
12.16.4. Analgesics
12.17. South Korea Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.17.1. Oral
12.17.2. Subcutaneous
12.17.3. Intravenous
12.18. Australia Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.18.1. Non-steroidal anti-inflammatories (NSAIDs)
12.18.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.18.3. Corticosteroids
12.18.4. Analgesics
12.19. Australia Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.19.1. Oral
12.19.2. Subcutaneous
12.19.3. Intravenous
12.20. ASEAN Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.20.1. Non-steroidal anti-inflammatories (NSAIDs)
12.20.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.20.3. Corticosteroids
12.20.4. Analgesics
12.21. ASEAN Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.21.1. Oral
12.21.2. Subcutaneous
12.21.3. Intravenous
12.22. Rest of Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
12.22.1. Non-steroidal anti-inflammatories (NSAIDs)
12.22.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.22.3. Corticosteroids
12.22.4. Analgesics
12.23. Rest of Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
12.23.1. Oral
12.23.2. Subcutaneous
12.23.3. Intravenous
12.24. Asia Pacific Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis
12.24.1. By Drug-Class
12.24.2. By Route of Administration
12.25. PEST Analysis
12.26. Key Trends
12.27. Key Developments

13. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Overview
13.3. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Drug-Class
13.4. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
13.4.1. Non-steroidal anti-inflammatories (NSAIDs)
13.4.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.4.3. Corticosteroids
13.4.4. Analgesics
13.5. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
13.5.1. Oral
13.5.2. Subcutaneous
13.5.3. Intravenous
13.6. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, by Country
13.7. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, by Country
13.7.1. GCC Countries
13.7.2. South Africa
13.7.3. Nigeria
13.7.4. Egypt
13.7.5. Rest of Middle East & Africa
13.8. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Analysis, by Country
13.9. GCC Countries Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
13.9.1. Non-steroidal anti-inflammatories (NSAIDs)
13.9.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.9.3. Corticosteroids
13.9.4. Analgesics
13.10. GCC Countries Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
13.10.1. Oral
13.10.2. Subcutaneous
13.10.3. Intravenous
13.11. South Africa Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
13.11.1. Non-steroidal anti-inflammatories (NSAIDs)
13.11.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.11.3. Corticosteroids
13.11.4. Analgesics
13.12. South Africa Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
13.12.1. Oral
13.12.2. Subcutaneous
13.12.3. Intravenous
13.13. Nigeria Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
13.13.1. Non-steroidal anti-inflammatories (NSAIDs)
13.13.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.13.3. Corticosteroids
13.13.4. Analgesics
13.14. Nigeria Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
13.14.1. Oral
13.14.2. Subcutaneous
13.14.3. Intravenous
13.15. Egypt Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
13.15.1. Non-steroidal anti-inflammatories (NSAIDs)
13.15.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.15.3. Corticosteroids
13.15.4. Analgesics
13.16. Egypt Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
13.16.1. Oral
13.16.2. Subcutaneous
13.16.3. Intravenous
13.17. Rest of Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
13.17.1. Non-steroidal anti-inflammatories (NSAIDs)
13.17.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.17.3. Corticosteroids
13.17.4. Analgesics
13.18. Rest of Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
13.18.1. Oral
13.18.2. Subcutaneous
13.18.3. Intravenous
13.19. Middle East & Africa Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis
13.19.1. By Drug-Class
13.19.2. By Route of Administration
13.20. PEST Analysis
13.21. Key Trends
13.22. Key Developments

14. South America Rheumatoid Arthritis Pharmacotherapeutics Market Analysis
14.1. Key Findings
14.2. South America Rheumatoid Arthritis Pharmacotherapeutics Market Overview
14.3. South America Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, By Drug-Class
14.4. South America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
14.4.1. Non-steroidal anti-inflammatories (NSAIDs)
14.4.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.4.3. Corticosteroids
14.4.4. Analgesics
14.5. South America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
14.5.1. Oral
14.5.2. Subcutaneous
14.5.3. Intravenous
14.6. South America Rheumatoid Arthritis Pharmacotherapeutics Market Value Share Analysis, by Country
14.7. South America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, by Country
14.7.1. Brazil
14.7.2. Colombia
14.7.3. Argentina
14.7.4. Rest of South America
14.8. South America Rheumatoid Arthritis Pharmacotherapeutics Market Analysis, by Country
14.9. Brazil Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
14.9.1. Non-steroidal anti-inflammatories (NSAIDs)
14.9.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.9.3. Corticosteroids
14.9.4. Analgesics
14.10. Brazil Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
14.10.1. Oral
14.10.2. Subcutaneous
14.10.3. Intravenous
14.11. Colombia Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
14.11.1. Non-steroidal anti-inflammatories (NSAIDs)
14.11.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.11.3. Corticosteroids
14.11.4. Analgesics
14.12. Colombia Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
14.12.1. Oral
14.12.2. Subcutaneous
14.12.3. Intravenous
14.13. Argentina Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
14.13.1. Non-steroidal anti-inflammatories (NSAIDs)
14.13.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.13.3. Corticosteroids
14.13.4. Analgesics
14.14. Argentina Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
14.14.1. Oral
14.14.2. Subcutaneous
14.14.3. Intravenous
14.15. Rest of South America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Drug-Class
14.15.1. Non-steroidal anti-inflammatories (NSAIDs)
14.15.2. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.15.3. Corticosteroids
14.15.4. Analgesics
14.16. Rest of South America Rheumatoid Arthritis Pharmacotherapeutics Market Forecast, By Route of Administration
14.16.1. Oral
14.16.2. Subcutaneous
14.16.3. Intravenous
14.17. South America Rheumatoid Arthritis Pharmacotherapeutics Market Attractiveness Analysis
14.17.1. By Drug-Class
14.17.2. By Route of Administration
14.18. PEST Analysis
14.19. Key Trends
14.20. Key Developments

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix

15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration

15.3. Company Profiles: Key Players
15.3.1. Amgen
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. Johnson & Johnson
15.3.3. Abbott
15.3.4. Abbvie Inc.
15.3.5. Pfizer Inc.
15.3.6. Celgene corporation
15.3.7. Bristol-Myers Squibb Company
15.3.8. Hoffman-La Roche Ltd.
15.3.9. UCB S.A.
15.3.10. Eli Lilly and Company
15.3.11. Gilead Sciences Inc.
15.3.12. Takeda Biosciences
15.3.13. Merck
15.3.14. Taisho Pharmaceuticals
15.3.15. Viela Bio
15.3.16. Perrigo
15.3.17. VetBiochem India pvt. Ltd.
15.3.18. Celgene corporation

16. Primary key Insights
  • INQUIRE BEFORE BUYING